FDA has now turned last week’s psychedelic executive order into a specific accelerated-review action: in an Apr. 24 announcement , the agency said it is issuing national priority vouchers to three companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD. In plain terms, FDA is offering a faster review pathway for some future drug applications. The key boundary: FDA’s announcement describes the drug-and-indication buckets, not the recipient names.
A CNPV — Commissioner’s National Priority Voucher — is an FDA Commissioner pilot-program tool that is separate from Breakthrough Therapy status and not the older transferable statutory priority review voucher. FDA’s program page says selected sponsors can receive enhanced communications, rolling review, and a target review window of roughly one to two months after a complete application is filed, while normal FDA safety and effectiveness standards still apply.
What the primary sources establish
The White House order directed the FDA Commissioner to provide CNPVs to appropriate psychedelic drugs with Breakthrough Therapy designation that meet the program criteria. FDA’s follow-up narrows that signal into three psychedelic-related product buckets: psilocybin/TRD, psilocybin/MDD, and methylone/PTSD.
COMPASS is the clean direct confirmation. In its own Apr. 24 release , COMPASS said FDA granted its NDA rolling-review request and selected COMP360, its proprietary synthetic psilocybin formulation, for the CNPV program in treatment-resistant depression.
The other two buckets have strong program-fit matches, but not the same confirmation. Usona has a psilocybin major-depressive-disorder program with Breakthrough Therapy designation and a Phase 3 uAspire trial. Transcend has TSND-201, a methylone PTSD program with Breakthrough Therapy designation and a Phase 3 trial. Otsuka announced an agreement to acquire Transcend, expected to close in Q2 2026 subject to conditions. None of those primary pages, as checked here, says Usona, Transcend, or Otsuka received a CNPV.
What others are saying
BioSpace’s coverage makes the caution explicit: FDA did not announce the recipient names, declined on-record comment, COMPASS later directly confirmed its voucher, and the other two recipients remain undisclosed even though Usona and Transcend match FDA’s descriptions.
Psychedelic Alpha goes further in its framing by naming Otsuka, COMPASS, and Usona. That is useful market context, but SCM is not treating secondary naming as recipient confirmation. Fierce Biotech’s earlier executive-order coverage is also useful for the timeline: it captured FDA Commissioner Marty Makary saying three vouchers were coming, while noting that the companies had not yet been revealed.
What this does — and does not — change
If the CNPV program works as described, it could matter for late-stage psychedelic developers because review mechanics can become a major bottleneck after pivotal data and a complete application. But the voucher is still a process acceleration tool. It is not an approval, not a finding that a drug is safe or effective, not a classwide rescheduling action, and not a guarantee that a one-to-two-month target will hold for every application.
The watch list is straightforward: an FDA update naming recipients; a Usona, Transcend, or Otsuka announcement; or a filing that names the relevant voucher and recipient relationship. Until that lands, the safest sentence is the narrow one: FDA described three psychedelic-related CNPVs, COMPASS directly confirmed one, and the remaining two are program-fit or media-framed rather than primary-confirmed recipients.